TissueBlue 0 . 025 % - Indications & Usage Section TissueBlue ( Brilliant Blue G Ophthalmic Solution ) 0 . 025 % is is a disclosing agent indicated to selectively stain the internal limiting membrane ( ILM ) .
TissueBlue ( Brilliant Blue G Ophthalmic Solution ) 0 . 025 % is is a disclosing agent indicated to selectively stain the internal limiting membrane ( ILM ) .
TissueBlue 0 . 025 % - Dosage & Administration Section TissueBlue 0 . 025 % is carefully injected into the Balanced Salt Solution ( BSS ) - filled vitreous cavity using a blunt cannula attached to the pre - filled syringe , without allowing the cannula to contact the retina or allowing TissueBlue to get under the retina .
Sufficient staining is expected within a few seconds .
Following staining , all excess dye should be removed from the vitreous cavity .
• Inject TissueBlue 0 . 025 % directly in a Balanced Salt Solution ( BSS ) - filled vitreous cavity .
• Excess TissueBlue should be removed from the vitreous cavity .
TissueBlue 0 . 025 % - Dosage forms & Strengths section TissueBlue ( Brilliant Blue G Ophthalmic Solution ) 0 . 025 % is a clear , bright blue , single - dose ophthalmic solution supplied in 2 . 25 mL syringes pre - filled to a volume of 0 . 5 mL .
TissueBlue ( Brilliant Blue G Ophthalmic Solution ) 0 . 025 % is supplied in 2 . 25 mL syringes filled to a volume of 0 . 5 mL .
TissueBlue 0 . 025 % - Contraindications section None None TissueBlue 0 . 025 % - Warnings and Precautions section Excessive Staining Excess TissueBlue 0 . 025 % should be removed from the eye immediately after staining .
Use of the Syringe Make sure the plunger moves smoothly before injecting the solution .
Do not use the product if the plunger does not move smoothly to prime the cannula .
Excessive staining : Excess TissueBlue 0 . 025 % should be removed from the eye immediately after staining .
Use of the syringe : Make sure the plunger moves smoothly before injecting the solution .
TissueBlue 0 . 025 % - Adverse Reactions section Adverse reactions that have been reported in procedures that included the use of Brilliant Blue G Ophthalmic Solution have often been associated with the surgical procedure .
These complications include retinal ( retinal break , tear , hemorrhage , and detachment ) and cataracts .
Adverse reactions that have been reported in procedures that included the use of TissueBlue 0 . 025 % have often been associated with the surgical procedure .
The complications include retinal ( retinal break , tear , hemorrhage , and detachment and cataracts .
To report SUSPECTED ADVERSE REACTIONS , contact Dutch Ophthalnic , USA at 1 - 800 - 75 - DUTCH or FDA at 1 - 800 - FDA - 1088 or www . fda . gov / medwatch TissueBlue 0 . 025 % - Use in specific populations section TissueBlue 0 . 025 % - Pregnancy section Risk Summary There are no available data on the use of TissueBlue 0 . 025 % in pregnant women to inform a drug associated risk .
Systemic absorption of TissueBlue 0 . 025 % in humans is expected to be negligible following intravitreal injection and subsequent removal of the drug at the completion of surgical procedures .
Due to the negligible systemic exposure , it is not expected that maternal use of TissueBlue 0 . 025 % will result in fetal exposure to the drug .
Adequate animal reproduction studies were not conducted with TissueBlue 0 . 025 % .
TissueBlue 0 . 025 % - Lactation section Risk Summary No data are available regarding the presence of Brilliant Blue G in human milk after intraocular administration of TissueBlue 0 . 025 % , or the effects on the breastfed infant or the effects on milk production .
However , breastfeeding is not expected to result in exposure of the child to Brilliant Blue G due to the expected negligible systemic exposure of BBG in humans following intravitreal injection and subsequent removal of the drug at the completion of surgical procedures .
TissueBlue 0 . 025 % - Pediatric use section The safety and effectiveness of TissueBlue 0 . 025 % in pediatric patients has not been established .
TissueBlue 0 . 025 % - Geriatric use section No overall differences in safety or effectiveness were observed between elderly and younger adult patients .
TissueBlue 0 . 025 % - Description section TissueBlue ( Brilliant Blue G Ophthalmic Solution ) 0 . 025 % is a sterile solution of BBG ( a dye ) .
Each mL of TissueBlue 0 . 025 % contains BBG 0 . 25 mg , Polyethylene Glycol 40 mg and Buffered Sodium Chloride solution ( 8 . 20 mg of sodium chloride , 3 . 10 mg sodium phosphate dibasic dodecahydrate , 0 . 30 mg sodium phosphate monobasic dihydrate , water for injection ) .
The pH range of TissueBlue 0 . 025 % Solution is between 7 . 3 and 7 . 6 .
The drug substance BBG has the chemical name Brilliant Blue G , a molecular weight of 854 . 02 and has the following chemical structure : Molecular formula : C 47 H 48 N 3 NaO 7 S 2 [ MULTIMEDIA ] [ MULTIMEDIA ] TissueBlue 0 . 025 % - Clinical Pharmacology section TissueBlue 0 . 025 % - Mechanism of action section Brilliant Blue G has been shown to selectively stain the ILM , but not the epiretinal membrane nor the retina , making it easier to visualize the membrane for removal , although the exact mechanism of this selectivity has not been elucidated .
TissueBlue 0 . 025 % - Nonclinical toxicology section TissueBlue 0 . 025 % - Nonclinical toxicology section Studies to evaluate the potential for carcinogenicity or impairment of fertility of TissueBlue 0 . 025 % have not been conducted .
Brilliant Blue G was not mutagenic in the Ames assay , the in vitro mouse lymphoma assay , or the in vivo rat micronucleus assay .
TissueBlue 0 . 025 % - How supplied section TissueBlue ( Brilliant Blue G Ophthalmic Solution ) , 0 . 025 % is supplied as 0 . 5 mL of Brilliant Blue G Ophthalmic Solution , 0 . 025 % in a sterile , single - dose Luer Lok , 2 . 25 mL glass syringe , with a grey rubber plunger stopper and tip cap with polypropylene plunger rod in a pre - formed polypropylene blister pouch sealed with a Tyvek ® lid .
NDC 68803 - 722 - 05 ( One 0 . 5 mL syringe ) NDC 68803 - 722 - 25 ( Carton of five 0 . 5 mL syringes ) TissueBlue 0 . 025 % - Storage and Handling section TissueBlue 0 . 025 % should be stored at 15 ° C to 25 ° C ( 59 ° F to 77 ° F ) .
Protect from light , frost and moisture .
Rx Only Distributed by : Dutch Ophthalmic , USA 10 Continental Drive , Bldg 1 Exeter , NH 03833 , USA Phone : 800 - 75 - DUTCH or 603 - 778 - 6929 Revision Date : 12 / 2019 Made in Germany All trademarks are the property of their respective owners .
Package Label - 0 . 5 mL TissueBlue ( Brilliant Blue G Ophthalmic Solution ) 0 . 025 % Staining Solution for Ophthalmic Surgery Protect from light , frost and moisture .
Store at 15 ° C to 25 ° C ( 59 ° F to 77 ° F ) .
Sterile .
Active ingredients / Ingrédient actif : Brilliant Blue G 0 . 025 % Inactive ingredients / Ingrédients inactifs : Water for injection , Sodium chloride , Sodium phosphate dibasic dihydrate , Sodium phosphate monobasic dihydrate , Polyethylene Glycol .
NDC 68803 - 722 - 05 ( One 0 . 5 mL syringe ) NDC 68803 - 722 - 25 ( Carton of five 0 . 5 mL syringes ) [ MULTIMEDIA ] [ MULTIMEDIA ]
